Spyre Therapeutics (SYRE) Other Non-Current Liabilities (2015 - 2026)
Spyre Therapeutics (SYRE) posted Other Non-Current Liabilities of $57.0 million for Q1 2026, up 1663.16% on a QoQ basis from $3.2 million in Q3 2025, and up 245.36% year-over-year from $16.5 million in Q1 2025.
Spyre Therapeutics (SYRE) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Other Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $57.0 million for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 245.36% year-over-year to $57.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.0 million (up 245.36% YoY) and the FY2024 annual result came in at $36.6 million, down 11.35% from the prior year.
- Other Non-Current Liabilities was $57.0 million for Q1 2026 at Spyre Therapeutics, up from $3.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $164.4 million in Q2 2023 and bottomed at $8000.0 in Q1 2022.
- A 5-year average of $41.3 million and a median of $36.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities tumbled 96.12% — and 2026, when it surged 245.36%.
- Spyre Therapeutics' Other Non-Current Liabilities stood at $8000.0 in 2022, then surged by 516275.0% to $41.3 million in 2023, then dropped by 11.35% to $36.6 million in 2024, then sank by 91.18% to $3.2 million in 2025, then jumped by 1663.16% to $57.0 million in 2026.
- Business Quant data shows SYRE's Other Non-Current Liabilities at $57.0 million in Q1 2026, $3.2 million in Q3 2025, and $16.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.95 Mn |
| Sep 30, 2025 | 3.23 Mn |
| Mar 31, 2025 | 16.49 Mn |
| Dec 31, 2024 | 36.62 Mn |
| Sep 30, 2024 | 36.16 Mn |
| Jun 30, 2024 | 39.56 Mn |
| Mar 31, 2024 | 39.11 Mn |
| Dec 31, 2023 | 41.31 Mn |
| Sep 30, 2023 | 20.69 Mn |
| Jun 30, 2023 | 164.40 Mn |
| Mar 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 16,000.00 |
| Sep 30, 2021 | 192,000.00 |
| Jun 30, 2021 | 200,000.00 |
| Mar 31, 2021 | 206,000.00 |
| Dec 31, 2020 | 214,000.00 |
| Sep 30, 2020 | 61,000.00 |
| Jun 30, 2020 | 68,000.00 |
| Mar 31, 2020 | 23,000.00 |
| Dec 31, 2019 | 31,000.00 |